You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of a BBB Model to Study Transendothelial Cell Migration
SBC: Flocel Inc. Topic: NIMHDESCRIPTION (provided by applicant): Increasing evidence indicates that systemic inflammation and the blood-brain barrier (BBB), which becomes the target of overreacting or misguided immune cells that determine BBB failure and immune extravasations into the brain parenchyma, are involved in the pathogenesis of neurological diseases such as meningitis, inflammation, Alzheimer's disease, and multipl ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Neuroprotective therapy of stroke with HUCNC and simvastatin
SBC: SANERON CCEL THERAPEUTICS, INC. Topic: NINDSDESCRIPTION (provided by applicant): There is a compelling need to develop therapeutic approaches specifically designed to reduce neurological deficits after stroke. Human umbilical cord blood cells (HUCBCs) treatment dose-dependently improves functional outcome after stroke. UCBCs are associated with a lower risk of graft-versus-host disease (GVHD), and UCBCs are younger than adult bone marrow st ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
In vivo expansion of human hepatocytes in Fah-/-Rag-/-Il2rg-/- mice
SBC: Yecuris Corporation Topic: NCRRDESCRIPTION (provided by applicant): The liver is the site of many metabolic processes, including metabolism of xenobiotics such as pharmaceutical compounds. Drug metabolism is highly species specific and can vary significantly between individuals of the same species. To date no reliable experimental system capable of predicting the human-specific metabolic conversion of candidate small molecules ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Lentiviral-MGMT gene transfer into hematopoietic stem cells
SBC: LENTIGEN CORPORATION Topic: NCIDESCRIPTION (provided by applicant): Therapeutic stem cell gene transfer relies on long-term gene expression achieved by integration of new DNA into the cellular genome. Current clinical trials featuring oncoretroviruses have encountered a number of roadblocks that include low levels of gene transfer, poor expression, and a recognized preferential insertion near promoter regions that increases the ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Recognition and Referral Skills for RAs- Alcohol-Drug Problems
SBC: PHASE 5, INC. Topic: NIAAADESCRIPTION (provided by applicant): Resident assistants (RAs) are often the first staff members at a college or university to learn that a student is engaged in alcohol or other drug abuse. This Phase II STTR application seeks support to further develop and test a web-based program called RA Resources (RAR) - Alcohol-Drug Problems. Phase 5, Inc. will conduct this theory-driven research project ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
HUCBC modulation of Alzheimer's-like pathology and behavioral changes
SBC: SANERON CCEL THERAPEUTICS, INC. Topic: NIADESCRIPTION (provided by applicant): In the past years, we have shown that human umbilical cord blood cells (HUCBC, U-CORD- CELL ) provide cognitive recovery in animal models of neurodegenerative disease. Infusion of HUCBC resulted in reduced infarct volume as well as in rescue of behavioral benefits in an animal model of stroke. We further showed that HUCBC infusion proved to be beneficial in ani ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Fluorescein for Sentinel Lymph Node Detection
SBC: VESTAN INC Topic: NCIDESCRIPTION (provided by applicant): In this Phase II STTR project, Vestan Medical Imaging, Inc. will complete the development and clinical evaluation of its proprietary formulation of a fluorescent drug and new medical devices for Sentinel Lymph Node (SLN) biopsy for the surgical treatment of melanoma and breast cancer. Vestan will partner with the University of Utah Huntsman Cancer Institute (HC ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
MyFAP: A Multimedia Intervention for Adolescents and Young Adults with FAP
SBC: Radiant Creative Group, LLC Topic: NCIDESCRIPTION (provided by applicant): In this Phase II STTR application, we will build upon work conducted in our successful Phase I project which established the technical merit, acceptability and feasibility of developing a Web-based intervention, MyFAP.org, for adolescents and young adults (AYAs) with familial adenomatous polyposis (FAP). The main research goal of Phase II is to evaluate the eff ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Characterization of human antibodies to sialyl-Lewis A (sLeA) derived from patien
SBC: MABVAX THERAPEUTICS, INC. Topic: NCIDESCRIPTION (provided by applicant): The carbohydrate antigen sialyl-Lewis a (sLea) is widely expressed on epithelial tumors of the gastrointestinal tract, on breast cancer cells, and also on small cell lung cancer cells but is expressed minimally or not at all on normal tissues. sLea serves as a ligand for epithelial leukocyte adhesion molecules and higher expression of sLea was observed in patie ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
User Adaptation of AAC Device Voices
SBC: BIOSPEECH INC Topic: NIDCDDESCRIPTION (provided by applicant): Augmentative and alternative communication devices with voice output (also known as Speech Generating Devices, or SGDs) enable individuals to speak by electronic means. Typical users of SGDs are individuals who have suffered from a stroke, traumatic brain injury, or who have neurodegenerative or neurodevelopmental disorders. In most cases, the user was able to ...
STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health